Published March 1, 2022
| Version v1
Patent
Open
Methods of treating cancers with CT45 targeted therapies
Creators
- 1. University of Chicago
- 2. Max Planck Institute
Contributors
Patent applicants:
Description
The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.
Files
US11261223.pdf
Files
(4.6 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:ea6dd82a9374f182bc39bea34c1a2e2d
|
4.6 MB | Preview Download |
Additional details
Identifiers
- Patent number
- US 11261223 B2
- Patent application number
- US 201716300267 A
- Other
- oai:uchicago.tind.io:7381
Dates
- Patent filed
-
2017-05-11